[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639281":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":57,"collaborators":60,"id":64,"slug":25,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":81,"conditions":82,"keywords":25,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"All India Institute of Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard conventionally fractionated PORT Arm A","ACTIVE_COMPARATOR","hypo-fractionated PORT Arm B",[13],"Radiation: Standard conventionally fractionated PORT",{"label":15,"type":16,"description":15,"interventionNames":17},"Hypo-fractionated PORT Arm B","EXPERIMENTAL",[18],"Radiation: hypo-fractionated PORT",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","Standard conventionally fractionated PORT","60Gy in 30 fractions over 6 weeks (5 fractions per week)",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"hypo-fractionated PORT","4Gy in 15 fractions over 3 weeks (5 fractions per week)",[15],[31],{"name":32,"affiliation":33,"role":34},"Dr. Aman Sharma","National cancer Institute, AIIMS, Jhajjar","PRINCIPAL_INVESTIGATOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":25,"email":39},"CONTACT","+917018529339","amans757@gmail.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":25,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Dr. Aman Sharma, Associate Professor, Radiation Oncology, NCI, AIIMS","RECRUITING","Jhajjar","Haryana","India","IN",{"type":49,"coordinates":50},"Point",[51,52],76.6565,28.6063,{"lat":52,"lon":51},[55],{"name":32,"role":37,"phone":38,"phoneExt":25,"email":56},"amans575@gmail.com",{"type":34,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Aman Sharma","Associate Professor",[61],{"name":62,"class":63},"Indian Council of Medical Research","OTHER_GOV","100639281",false,"NCT07573956","Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies","The HYPCON 3 Trial A Phase II\u002FIII Randomized Study Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant Radiation Therapy in Head and Neck Malignancies","Radiotherapy","Inclusion Criteria:\n\n* Patients with pT1-4 squamous cell carcinoma of oral cavity\u002F oropharynx\u002F larynx\u002F hypopharynx with any of the intermediate risk features:\n\n  * Positive lymph node (s)\n  * Perineural invasion\n  * Lympho-vascular invasion\n  * Close margins\n* Age 18-80yrs\n* ECOG performance status 0-1at time of surgery\n* Informed consent\n* Available FOR long term follow-up\n\nExclusion Criteria:\n\n* High risk factors following resection: positive-margin(s)and\u002For extra nodal extension (ENE)\n* pT1-2disease and no high-risk features (LVSI, PNI, Close margins,pN0)\n* Patients receiving Neo-adjuvant or concurrent Chemotherapy\n* Non-Squamous Histology\n* Distant metastasis\n* Synchronous or second primary malignancy outside of the oropharynx, oral cavity, larynx and hypopharynx\n* Pregnant females or nursing mothers due to the probability of congenital anomalies and potential of this regimen to harm nursing infants.\n* Prior Radiotherapy to head and neck region","ALL","18 Years","80 Years",{"count":75,"type":76},369,"ESTIMATED","INTERVENTIONAL",[79,80],"PHASE2","PHASE3","Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)",[83],"Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","2026-05-05",{"date":86,"type":87},"2026-05-07","ACTUAL",{"date":89,"type":87},"2026-02-10",{"date":91,"type":76},"2028-12-30",{"name":5,"class":6},1]